|
1
|
Singh AK, Kumar R and Pandey AK:
Hepatocellular carcinoma: Causes, mechanism of progression and
biomarkers. Curr Chem Genom Transl Med. 12:9–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Glantzounis GK, Kyrochristos ID, Ziogas
DE, Lykoudis EG and Roukos DH: Novel translational therapeutic
strategy by sequencing primary liver cancer genomes. Future Oncol.
13:1049–1052. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang B, Petrick JL, Kelly SP, Graubard BI,
Freedman ND and McGlynn KA: Adiposity across the adult life course
and incidence of primary liver cancer: The NIH-AARP cohort. Int J
Cancer. 141:271–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lan L, Zhao F, Cai Y, Wu RX and Meng Q:
Epidemiological analysis on mortality of cancer in China, 2015.
Zhonghua Liu Xing Bing Xue Za Zhi. 39:32–34. 2018.(In Chinese).
PubMed/NCBI
|
|
5
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bennett CL, Christie J, Ramsdell F,
Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT,
Chance PF and Ochs HD: The immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused
by mutations of FOXP3. Nat Genet. 27:20–21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malik S and Awasthi A: Transcriptional
control of Th9 cells: Role of foxo1 in interleukin-9 induction.
Front Immunol. 9:9952018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wada M, Tsuchikawa T, Kyogoku N, Abiko T,
Miyauchi K, Takeuchi S, Kuwatani T, Shichinohe T, Miyahara Y,
Kageyama S, et al: Clinical implications of
CD4+CD25+Foxp3+Regulatory T cell
frequencies after CHP--MAGE-A4 cancer vaccination. Anticancer Res.
38:1435–1444. 2018.PubMed/NCBI
|
|
9
|
Lin SZ, Chen KJ, Xu ZY, Chen H, Zhou L,
Xie HY and Zheng SS: Prediction of recurrence and survival in
hepatocellular carcinoma based on two cox models mainly determined
by FoxP3+ regulatory T cells. Cancer Prev Res (Phila). 6:594–602.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Triulzi T, Tagliabue E, Balsari A and
Casalini P: FOXP3 expression in tumor cells and implications for
cancer progression. J Cell Physiol. 228:30–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McInnes N, Sadlon TJ, Brown CY, Pederson
S, Beyer M, Schultze JL, McColl S, Goodall GJ and Barry SC: FOXP3
and FOXP3-regulated microRNAs suppress SATB1 in breast cancer
cells. Oncogene. 31:1045–1054. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Merlo A, Casalini P, Carcangiu ML,
Malventano C, Triulzi T, Mènard S, Tagliabue E and Balsari A: FOXP3
expression and overall survival in breast cancer. J Clin Oncol.
27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ebert LM, Tan BS, Browning J, Svobodova S,
Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D, et
al: The regulatory T cell-associated transcription factor FoxP3 is
expressed by tumor cells. Cancer Res. 68:3001–3009. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen DJ, Li XS, Zhao H, Shi XL, Zhang HH,
Fan ZY, Yao YM and DU N: Inhibitory effect of lentiviral-mediated
RNA on the expression of Foxp3 protein in melanoma cells. Xi Bao Yu
Fen Zi Mian Yi Xue Za Zhi. 28:337–339. 2012.(In Chinese).
PubMed/NCBI
|
|
15
|
Kobayashi N, Hiraoka N, Yamagami W, Ojima
H, Kanai Y, Kosuge T, Nakajima A and Hirohashi S: FOXP3+ regulatory
T cells affect the development and progression of
hepatocarcinogenesis. Clin Cancer Res. 13:902–911. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang WH, Jiang CL, Yan W, Zhang YH, Yang
JT, Zhang C, Yan B, Zhang W, Han W, Wang JZ and Zhang YQ: FOXP3
expression and clinical characteristics of hepatocellular
carcinoma. World J Gastroenterol. 16:5502–5509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi JY, Ma LJ, Zhang JW, Duan M, Ding ZB,
Yang LX, Cao Y, Zhou J, Fan J, Zhang X, et al: FOXP3 Is a HCC
suppressor gene and Acts through regulating the TGF-β/Smad2/3
signaling pathway. BMC Cancer. 17:6482017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagasawa T: CXC chemokine ligand 12
(CXCL12) and its receptor CXCR4. J Mol Med. 92:433–439. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Dai LI and Zhou R: Association
between preeclampsia and the CXC chemokine family (Review). Exp
Ther Med. 9:1572–1576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou XM, He L, Hou G, Jiang B, Wang YH and
Zhao L: Clinicopathological significance of CXCR4 in non-small cell
lung cancer. Drug Des Devel Ther. 9:1349–1358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Izumi D, Ishimoto T, Miyake K, Sugihara H,
Eto K, Sawayama H, Yasuda T, Kiyozumi Y, Kaida T, Kurashige J, et
al: CXCL12/CXCR4 activation by cancer-associated fibroblasts
promotes integrin β1 clustering and invasiveness in gastric cancer.
Int J Cancer. 138:1207–1219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rave-Frank M, Tehrany N, Kitz J, Leu M,
Weber HE, Burfeind P, Schliephake H, Canis M, Beissbarth T,
Reichardt HM and Wolff HA: Prognostic value of CXCL12 and CXCR4 in
inoperable head and neck squamous cell carcinoma. Strahlenther
Onkol. 192:47–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fontanella R, Pelagalli A, Nardelli A,
D'Alterio C, Ieranò C, Cerchia L, Lucarelli E, Scala S and Zannetti
A: A novel antagonist of CXCR4 prevents bone marrow-derived
mesenchymal stem cell-mediated osteosarcoma and hepatocellular
carcinoma cell migration and invasion. Cancer Lett. 370:100–107.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi JY, Yang LX, Wang ZC, Wang LY, Zhou J,
Wang XY, Shi GM, Ding ZB, Ke AW, Dai Z, et al: CC chemokine
receptor-like 1 functions as a tumour suppressor by impairing
CCR7-related chemotaxis in hepatocellular carcinoma. J Pathol.
235:546–558. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hao M, Zheng J, Hou K and Wang J, Chen X,
Lu X, Bo J, Xu C, Shen K and Wang J: Role of chemokine receptor
CXCR7 in bladder cancer progression. Biochem Pharmacol. 84:204–214.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Benredjem B, Girard M, Rhainds D, St-Onge
G and Heveker N: Mutational analysis of atypical chemokine receptor
3 (ACKR3/CXCR7) interaction with its chemokine ligands CXCL11 and
CXCL12. J Biol Chem. 292:31–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burns JM, Summers BC, Wang Y, Melikian A,
Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ,
et al: A novel chemokine receptor for SDF-1 and I-TAC involved in
cell survival, cell adhesion, and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Lu Z, Liang Z, Ji D, Zhang P, Liu Q,
Zheng X and Yao Y: Metastasis-associated in colon cancer-1 is
associated with poor prognosis in hepatocellular carcinoma, partly
by promoting proliferation through enhanced glucose metabolism. Mol
Med Rep. 12:426–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wiedmann MW and Mossner J: Molecular
targeted therapy of hepatocellular carcinoma-results of the first
clinical studies. Curr Cancer Drug Targets. 11:714–733. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tabrizian P, Jibara G, Shrager B, Schwartz
M and Roayaie S: Recurrence of hepatocellular cancer after
resection: Patterns, treatments, and prognosis. Ann Surg.
261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lopes JE, Torgerson TR, Schubert LA,
Anover SD, Ocheltree EL, Ochs HD and Ziegler SF: Analysis of FOXP3
reveals multiple domains required for its function as a
transcriptional repressor. J Immunol. 177:3133–3142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rudensky AY: Regulatory T cells and Foxp3.
Immunol Rev. 241:260–268. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grimmig T, Kim M, Germer CT, Gasser M and
Waaga-Gasser AM: The role of FOXP3 in disease progression in
colorectal cancer patients. Oncoimmunology. 2:e245212013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cunha LL, Morari EC, Nonogaki S, Soares
FA, Vassallo J and Ward LS: Foxp3 expression is associated with
aggressiveness in differentiated thyroid carcinomas. Clinics.
67:483–488. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang L, Mei M, Sun X, et al: Expression
and significance of Foxp3 in hepatocellular carcinoma. Shandong Med
J. 48:8–11. 2010.(In Chinese).
|
|
37
|
Niu J, Jiang C, Li C, Liu L, Li K, Jian Z
and Gao T: Foxp3 expression in melanoma cells as a possible
mechanism of resistance to immune destruction. Cancer Immunol
Immunother. 60:1109–1118. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J
and Wu C: Expression of costimulatory molecules B7-H1, B7-H4 and
Foxp3+ Tregs in gastric cancer and its clinical significance. Int J
Clin Oncol. 20:273–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fu S, Zhang N, Yopp AC, Chen D, Mao M,
Chen D, Zhang H, Ding Y and Bromberg JS: TGF-beta induces Foxp3 +
T-regulatory cells from CD4+CD25-precursors. Am J Transplant.
4:1614–1627. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng K, Li HY, Su XL, Wang XY, Tian T, Li
F and Ren GS: Chemokine receptor CXCR7 regulates the invasion,
angiogenesis and tumor growth of human hepatocellular carcinoma
cells. J Exp Clin Cancer Res. 29:312010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xue TC, Chen RX, Han D, Chen J, Xue Q, Gao
DM, Sun RX, Tang ZY and Ye SL: Down-regulation of CXCR7 inhibits
the growth and lung metastasis of human hepatocellular carcinoma
cells with highly metastatic potential. Exp Ther Med. 3:117–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sutton A, Friand V, Brulé-Donneger S,
Chaigneau T, Ziol M, Sainte-Catherine O, Poiré A, Saffar L, Kraemer
M, Vassy J, et al: Stromal cell-derived factor-1/chemokine (C-X-C
motif) ligand 12 stimulates human hepatoma cell growth, migration,
and invasion. Mol Cancer Res. 5:21–33. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Monnier J, Boissan M, L'Helgoualc'h A,
Lacombe ML, Turlin B, Zucman-Rossi J, Théret N, Piquet-Pellorce C
and Samson M: CXCR7 is up-regulated in human and murine
hepatocellular carcinoma and is specifically expressed by
endothelial cells. Eur J Cancer. 48:138–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zheng Y and Rudensky AY: Foxp3 in control
of the regulatory T cell lineage. Nat Immunol. 8:457–462. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Overbeck-Zubrzycka D, Ali S, Kirby J and
Lennard T: FOXP3 transcription factor regulates metastatic spread
of breast cancer via control of expression of CXCR4 chemokine
receptor. Br J Surg. 98:842011.PubMed/NCBI
|
|
46
|
Duda DG, Kozin SV, Kirkpatrick ND, Xu L,
Fukumura D and Jain RK: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway
inhibition: An emerging sensitizer for anticancer therapies? Clin
Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI
|
